Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Nicoletta Colombo(University of Milano-Bicocca), Paul DiSilvestro(Women & Infants Hospital of Rhode Island), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), Charlie Gourley(Edinburgh Cancer Research), Michael Friedländer(Prince of Wales Hospital), Alexandra Léary(Institut Gustave Roussy), Giovanni Scambia(Agostino Gemelli University Polyclinic), William H. Bradley(Froedtert Hospital), Elizabeth Lowe(AstraZeneca (United States)), Cara Mathews(Brown University), Gabe S. Sonke(Oncode Institute), Carol Aghajanian(Memorial Sloan Kettering Cancer Center), Joyce F. Liu(Duke University), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ana Oaknin(Hebron University), Kathleen N. Moore(University of Oklahoma Medical Center), Amit M. Oza(Ontario Institute for Cancer Research), Ralph Bloomfield(AstraZeneca (United Kingdom)), Anne Floquet(Institut Bergonié), Jae‐Weon Kim(Seoul National University), Alla Lisyanskaya(City Clinical Oncology Center)
Cited by 37
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k